Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole for Antipsychotic-Induced Hyperprolactinemia
NCT01085383Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Apr 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in antipsychotic-induced hyperprolactinemia, sponsored by University of Oxford. Primary endpoint: Normalization or reduction in prolactin sufficient to restore gonadal function at 2 years. Started Apr 2010; status: completed.
02
Drugs
aripiprazole
03
Conditions
antipsychotic-induced hyperprolactinemia
Beyond the preview
Go deeper on NCT01085383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085383.